Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
Clin Mol Hepatol 2019;25(1):30-36. Published online January 23, 2019
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.
Citations
Citations to this article as recorded by
Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang The Journal of Biomedical Research.2024; 38(5): 464. CrossRef
Laboratory Biochemical and Hematological Parameters: Early Predictive Biomarkers for Diagnosing Hepatitis C Virus Infection Saeede Bagheri, Ghazaleh Behrouzian Fard, Nasrin Talkhi, Davoud Rashidi Zadeh, Naser Mobarra, Seyedmahdi Mousavinezhad, Fatemeh Mirzaeian Khamse, Mahdi Hosseini Bafghi Journal of Clinical Laboratory Analysis.2024;[Epub] CrossRef
Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study Vito Fiore, Andrea De Vito, Elena Rastrelli, Valentina Manca, Giuseppe De Matteis, Roberto Ranieri, Emanuele Pontali, Nicholas Geremia, Sandro Panese, Giulio Starnini, Giordano Madeddu, Sergio Babudieri Viruses.2023; 15(12): 2414. CrossRef
Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice Nadia Marascio, Salvatore Rotundo, Angela Quirino, Giovanni Matera, Maria Carla Liberto, Chiara Costa, Alessandro Russo, Enrico Maria Trecarichi, Carlo Torti World Journal of Gastroenterology.2022; 28(12): 1226. CrossRef
HCV inhibits M2a, M2b and M2c macrophage polarization via HCV core protein engagement with Toll‑like receptor 2 Shixing Zhao, Meng Si, Xianpei Deng, Dengqin Wang, Lingbin Kong, Qianqian Zhang Experimental and Therapeutic Medicine.2022;[Epub] CrossRef
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment Daniela Zago, Irene Pozzetto, Monia Pacenti, Giuseppina Brancaccio, Silvia Ragolia, Monica Basso, Saverio Giuseppe Parisi The Open Microbiology Journal.2022;[Epub] CrossRef
The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview Nadia Marascio, Carmen De Caro, Angela Quirino, Maria Mazzitelli, Emilio Russo, Carlo Torti, Giovanni Matera Journal of Clinical Medicine.2022; 11(19): 5936. CrossRef
Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia Nikolay Pimenov, Dmitry Kostyushev, Svetlana Komarova, Anastasia Fomicheva, Alexander Urtikov, Olga Belaia, Karina Umbetova, Olga Darvina, Natalia Tsapkova, Vladimir Chulanov Pathogens.2022; 11(12): 1482. CrossRef
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection Pil Soo Sung, Eui-Cheol Shin Journal of Clinical Medicine.2021; 10(2): 221. CrossRef
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level Carlo Torti, Vincenzo Scaglione, Bruno Mario Cesana, Chiara Costa, Nadia Marascio, Elisabetta Schiaroli, Chiara Busti, Sabrina Bastianelli, Maria Mazzitelli, Enrico Maria Trecarichi, Daniela Francisci Health Science Reports.2021;[Epub] CrossRef
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Martín Soñora, Juan Cristina, Gonzalo Moratorio, Nelia Hernández, Pilar Moreno BMC Infectious Diseases.2021;[Epub] CrossRef
Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy Nadia Marascio, Angela Costantino, Stefania Taffon, Alessandra Lo Presti, Michele Equestre, Roberto Bruni, Giulio Pisani, Giorgio Settimo Barreca, Angela Quirino, Enrico Maria Trecarichi, Chiara Costa, Maria Mazzitelli, Francesca Serapide, Giovanni Matera Journal of Clinical Medicine.2021; 10(8): 1655. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals Pil Soo Sung, Eui-Cheol Shin International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018) Nadia Marascio, Maria Mazzitelli, Giuseppe G.M. Scarlata, Aida Giancotti, Giorgio S. Barreca, Angelo G. Lamberti, Francesca Divenuto, Chiara Costa, Enrico M. Trecarichi, Giovanni Matera, Maria C. Liberto, Carlo Torti The Open Microbiology Journal.2020; 14(1): 84. CrossRef
microRNA-99a Restricts Replication of Hepatitis C Virus by Targeting mTOR and De Novo Lipogenesis Eun Byul Lee, Pil Soo Sung, Jung-Hee Kim, Dong Jun Park, Wonhee Hur, Seung Kew Yoon Viruses.2020; 12(7): 696. CrossRef
Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks Carlos García-Crespo, María Eugenia Soria, Isabel Gallego, Ana Isabel de Ávila, Brenda Martínez-González, Lucía Vázquez-Sirvent, Jordi Gómez, Carlos Briones, Josep Gregori, Josep Quer, Celia Perales, Esteban Domingo Journal of Clinical Medicine.2020; 9(11): 3450. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti
Clin Mol Hepatol 2018;24(2):151-162. Published online April 24, 2018
Background/Aims Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection.
Methods A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12).
Results In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ 2 =3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup.
Conclusions In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.
Citations
Citations to this article as recorded by
Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections Feng Chen, Shan-Shan Wu, Chao Chen, Cheng Zhou World Journal of Hepatology.2024; 16(2): 177. CrossRef
Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang The Journal of Biomedical Research.2024; 38(5): 464. CrossRef
Stem Cells in Kidney Ischemia: From Inflammation and Fibrosis to Renal Tissue Regeneration Rosario Cianci, Mariadelina Simeoni, Eleonora Cianci, Oriana De Marco, Antonio Pisani, Claudio Ferri, Antonietta Gigante International Journal of Molecular Sciences.2023; 24(5): 4631. CrossRef
Renal Stem Cells, Renal Resistive Index, and Neutrophil Gelatinase Associated
Lipocalin Changes After Revascularization in Patients With Renovascular Hypertension
and Ischemic Nephropathy Rosario Cianci, Mariadelina Simeoni, Antonietta Gigante, Adolfo Marco Perrotta, Sonia Ronchey, Nicola Mangialardi, Annalisa Schioppa, Oriana De Marco, Eleonora Cianci, Cristiana Barbati, Silvia Lai, Claudio Ferri Current Pharmaceutical Design.2023; 29(2): 133. CrossRef
Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed Rossella Di Paola, Ananya De, Anna Capasso, Sofia Giuliana, Roberta Ranieri, Carolina Ruosi, Antonella Sciarra, Caterina Vitagliano, Alessandra F. Perna, Giovambattista Capasso, Mariadelina Simeoni Journal of Personalized Medicine.2023; 13(5): 813. CrossRef
INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease Anil Arora, Ashish Kumar, Narayan Prasad, Ajay Duseja, Subrat K. Acharya, Sanjay K. Agarwal, Rakesh Aggarwal, Anil C. Anand, Anil K. Bhalla, Narendra S. Choudhary, Yogesh K. Chawla, Radha K. Dhiman, Vinod K. Dixit, Natarajan Gopalakrishnan, Ashwani Gupta, Journal of Clinical and Experimental Hepatology.2021; 11(3): 354. CrossRef
HCV cirrhotic patients treated with direct‐acting antivirals: Detection of tubular dysfunction and resolution after viral clearance Elisa Biliotti, Donatella Palazzo, Francesca Tinti, Maria Domenica D'Alessandro, Rozenn Esvan, Raffaella Labriola, Andrea Cappoli, Ilaria Umbro, Lorenzo Volpicelli, Alessandra Bachetoni, Erica Villa, Anna Paola Mitterhofer, Paola Rucci, Gloria Taliani Liver International.2021; 41(1): 158. CrossRef
Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals Yen-Chun Chen, Chen-Hao Li, Ping-Hung Ko, Chi-Che Lee, Ru-Jiang Syu, Chih-Wei Tseng, Kuo-Chih Tseng, Chen-Hua Liu PLOS ONE.2021; 16(8): e0256505. CrossRef
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1. CrossRef
Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy) Vincenzo Scaglione, Maria Mazzitelli, Chiara Costa, Vincenzo Pisani, Giuseppe Greco, Francesca Serapide, Rosaria Lionello, Valentina La Gamba, Nadia Marascio, Enrico Maria Trecarichi, Carlo Torti Medicina.2020; 56(3): 101. CrossRef
Looking beyond Entecavir to discover Gitelman Syndrome in a 50 year-old man M Simeoni, V Columbano, Y Suzumoto, L Salviano, G Capolongo, M Zacchia, F Del Vecchio Blanco, A F Perna, V Nigro, G Capasso, F Trepiccione QJM: An International Journal of Medicine.2020; 113(10): 739. CrossRef
Hepatitis C virus and the kidney Stanislas Pol, Lucia Parlati, Michel Jadoul Nature Reviews Nephrology.2019; 15(2): 73. CrossRef
Background/Aims Although the detrimental effects of several dietary components on the promotion of nonalcoholic fatty liver disease are well known, no studies have assessed the role of dietary vitamin B6. Moreover, studies on the associations between dietary components or body composition indices and liver steatosis assessed by transient elastography are rare. Our aim was to identify the nutritional factors and anthropometric parameters associated with liver steatosis.
Methods In this cross-sectional study, we enrolled 168 individuals (35% obese) who underwent a liver steatosis assessment by Controlled Attenuation Parameter measurement and nutritional assessment.
Results Tertiles of vitamin B6 intake were positively associated with hepatic steatosis (B=1.89, P=0.026, confidence interval [CI] 0.03-0.80) as well as with triglycerides, glucose, alanine aminotransferase (ALT), and body mass index . In obese individuals, after multivariable analysis, the Controlled Attenuation Parameter score was still associated with triglycerides, ALT, and total protein intake (B=0.56, P=0.01, CI 0.10-1.02). Participants in tertile I (low intake) had a lower Controlled Attenuation Parameter than those in tertile III (P=0.01).
Conclusions We found a positive association between hepatic steatosis or Controlled Attenuation Parameter score and vitamin B6/total protein intake, probably related to the high intake of meat. Vitamin B6 might have a pathogenic role related to the increase of hepatic steatosis.
Citations
Citations to this article as recorded by
From Fly to Human: Translational Relevance of Drosophila Models in the Study of Vitamin B6 and Cancer Relationship Fiammetta Vernì, Chiara Angioli, Angelo Ferriero, Beatrice Agostini International Journal of Molecular Sciences.2026; 27(6): 2877. CrossRef
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage Haiyuan Shen, Liangliang Zhou, Yuanru Yang, Hang Shu, Dongqing Wu, Simin Yang, Linxi Xie, Lei Yang, Shanfei Tian, Xinru Zhang, Rui Ma, Ling Jiang, Man Jiang, Hao Zhang, Yan Wang, Hejiao Zhang, Shan Gao, Long Xu, Hua Wang Hepatology Communications.2025;[Epub] CrossRef
Tocotrienol-rich fraction in medium-chain triglyceride carrier upregulates purine metabolism in non-alcoholic fatty liver disease (NAFLD) animal model Mohd Danial Mohd Efendy Goon, Sharaniza Ab-Rahim, Siti Hamimah Sheikh Abdul Kadir, Effendi Ibrahim, Musalmah Mazlan, Normala Abd Latip Egyptian Liver Journal.2025;[Epub] CrossRef
Exploring the role of gut microbiota in inflammatory bowel disease patients comorbid with non-alcoholic fatty liver disease Jiachen Hu, Chen Zhou, Lu Zhang, Yuzhu Chen, Jun Li, Junxia Li, Liping Duan Gut Pathogens.2025;[Epub] CrossRef
Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan International Journal of Molecular Sciences.2025; 26(19): 9625. CrossRef
A nutraceutical with Citrus bergamia and Cynara cardunculus improves endothelial function in adults with non-alcoholic fatty liver disease Samantha Maurotti, Roberta Pujia, Yvelise Ferro, Rosario Mare, Raffaella Russo, Adriana Coppola, Carmine Gazzaruso, Tiziana Montalcini, Arturo Pujia, Sara Paone, Vincenzo Mollace, Elisa Mazza Nutrition.2024; 118: 112294. CrossRef
Associations between one-carbon metabolism and valproic acid-induced liver dysfunction in epileptic patients Jingwei Zhu, Zhe Wang, Xiaotong Sun, Dan Wang, Xinbo Xu, Liping Yang, Jiangdong Du, Zhimei Zhou, Yanhua Qi, Linfeng Ma Frontiers in Pharmacology.2024;[Epub] CrossRef
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective Yansong Fu, Zhipeng Wang, Hong Qin Metabolites.2024; 14(4): 218. CrossRef
Supplementation of Micro- and Macronutrients—A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease Magdalena Tyczyńska, Gabriela Hunek, Martyna Szczasny, Adam Brachet, Jacek Januszewski, Alicja Forma, Piero Portincasa, Jolanta Flieger, Jacek Baj International Journal of Molecular Sciences.2024; 25(9): 4916. CrossRef
Exploring the role of pyridoxal kinase: a key player in vitamin B6 metabolism Pallabi Banerjee, Risha Singh, Rajkumari Urmi, Manisha Singh, Anshuman Chandra, Nagendra Singh, Imteyaz Qamar Endocrinology & Metabolism International Journal.2024; 12(3): 68. CrossRef
Schisandrin A alleviates non-alcoholic fatty liver disease by improving liver metabolic disorders and suppressing the GSK3β signaling pathway Li Zong, Rui Xu, Yunxia Sun, Junjie Qiu, Huihui Tao, Chengyu Shentu, Hongxia Niu, Tengfei Xu, Yuan Zhou Food Bioscience.2024; 62: 105245. CrossRef
Association of nutrient intake with non-alcoholic fatty liver disease and liver steatosis in adult Indian population – A case control study Swapna Chaturvedi, Divya Tripathi, Naval Kishore Vikram, Kumble S. Madhusudan, Ravindra Mohan Pandey, Neena Bhatia Human Nutrition & Metabolism.2023; 32: 200188. CrossRef
A promising antifibrotic drug, pyridoxamine attenuates thioacetamide-induced liver fibrosis by combating oxidative stress, advanced glycation end products, and balancing matrix metalloproteinases Aliah R. Alshanwani, Hanan Hagar, Sameerah Shaheen, Ahlam M. Alhusaini, Maha M. Arafah, Laila M. Faddah, Fatima MB. Alharbi, Arun K. Sharma, Amel Fayed, Amira M. Badr European Journal of Pharmacology.2022; 923: 174910. CrossRef
Vitaminler ve Non Alkolik Yağlı Karaciğer Hastalığı Aziz KILINÇ, Yasemin AKDEVELİOĞLU Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi.2022; 6(2): 383. CrossRef
Hepatoprotective Effects of Ixeris chinensis on Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice: An Integrated Gut Microbiota and Metabolomic Analysis Wenjie Jin, Sungbo Cho, Namujila Laxi, Terigele Bao, Lili Dai, Hongzhen Yu, Rigeer Qi, Junqing Zhang, Genna Ba, Minghai Fu Molecules.2022; 27(10): 3148. CrossRef
Association between the index of nutritional quality and lipid profile in adult women Saheb Abbas Torki, Effat Bahadori, Soheila Shekari, Soroor Fathi, Maryam Gholamalizadeh, Naeemeh Hasanpour Ardekanizadeh, Bahareh Aminnezhad, Mina Ahmadzadeh, Mahtab Sotoudeh, Fatemeh Shafie, Samira Rastgoo, Farhad Vahid, Saeid Doaei Endocrinology, Diabetes & Metabolism.2022;[Epub] CrossRef
Citrus Bergamia and Cynara Cardunculus Reduce Serum Uric Acid in Individuals with Non-Alcoholic Fatty Liver Disease Yvelise Ferro, Samantha Maurotti, Elisa Mazza, Roberta Pujia, Angela Sciacqua, Vincenzo Musolino, Vincenzo Mollace, Arturo Pujia, Tiziana Montalcini Medicina.2022; 58(12): 1728. CrossRef
Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial Takashi Kobayashi, Takaomi Kessoku, Anna Ozaki, Michihiro Iwaki, Yasushi Honda, Yuji Ogawa, Kento Imajo, Masato Yoneda, Satoru Saito, Atsushi Nakajima Journal of Clinical Biochemistry and Nutrition.2021; 68(2): 181. CrossRef
The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease Mikkel Parsberg Werge, Adrian McCann, Elisabeth Douglas Galsgaard, Dorte Holst, Anne Bugge, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud Journal of Clinical Medicine.2021; 10(5): 1081. CrossRef
The multifaceted role of vitamin B6 in cancer: Drosophila as a model system to investigate DNA damage Roberto Contestabile, Martino Luigi di Salvo, Victoria Bunik, Angela Tramonti, Fiammetta Vernì Open Biology.2020;[Epub] CrossRef
Vitamin B6 and Diabetes: Relationship and Molecular Mechanisms Elisa Mascolo, Fiammetta Vernì International Journal of Molecular Sciences.2020; 21(10): 3669. CrossRef
Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years Yvelise Ferro, Tiziana Montalcini, Elisa Mazza, Daniela Foti, Elvira Angotti, Micaela Gliozzi, Saverio Nucera, Sara Paone, Ezio Bombardelli, Ilaria Aversa, Vincenzo Musolino, Vincenzo Mollace, Arturo Pujia Frontiers in Endocrinology.2020;[Epub] CrossRef
Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases Rocco Spagnuolo, Tiziana Montalcini, Daniele De Bonis, Yvelise Ferro, Cristina Cosco, Elisa Mazza, Stefano Romeo, Patrizia Doldo, Arturo Pujia Nutrients.2019; 11(2): 303. CrossRef
Association Between Index of Nutritional Quality and Nonalcoholic Fatty Liver Disease: The Role of Vitamin D and B Group Farhad Vahid, Azita Hekmatdoost, Sousan Mirmajidi, Saeid Doaei, Diyako Rahmani, Zeinab Faghfoori The American Journal of the Medical Sciences.2019; 358(3): 212. CrossRef
Vitamin B6 deficiency in new born rats affects hepatic cardiolipin composition and oxidative phosphorylation Carmen Wolke, Sarah Gürtler, Daniela Peter, Jens Weingärtner, Grazyna Domanska, Uwe Lendeckel, Lorenz Schild Experimental Biology and Medicine.2019; 244(18): 1619. CrossRef
Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease Seung Up Kim, Mi Young Jeon, Tae Seop Lim The Korean Journal of Gastroenterology.2019; 74(6): 341. CrossRef
Vitamin B6 improves blood parameters in rats fed a protein-deficient diet and subjected to moderate, long-term exercise Bolesław Kalicki, Aneta Lewicka, Krystyna Jęderka, Monika Leśniak, Justyna Marszałkowska-Jakubik, Sławomir Lewicki Central European Journal of Immunology.2019; 44(1): 23. CrossRef
Effect of the replacement of dietary vegetable oils with a low dose of extravirgin olive oil in the Mediterranean Diet on cognitive functions in the elderly Elisa Mazza, Antonietta Fava, Yvelise Ferro, Stefania Rotundo, Stefano Romeo, Domenico Bosco, Arturo Pujia, Tiziana Montalcini Journal of Translational Medicine.2018;[Epub] CrossRef
First
Prev
